The latest Digital Health news industry round-up includes an award of £1.4m for Mendelian to further develop its AI solutions, a pilot for a state-of-the-art prehabilitation programme at James Paget University Hospitals and the…
Continue Reading
Accelerator alumni, Mendelian, Cibiltech and Ibex, have secured funding through the third competition of the Artificial Intelligence in Health and Care Awards.The awards are run by the NHS AI Lab in partnership with the…
Continue Reading
Friedrich’s ataxia, an ultra-rare disease that causes progressively worsening muscle function that ultimately leads to death, now has its first FDA-approved therapy. The regulator has given the green light to a Reata Pharmaceuticals drug…
Continue Reading
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of its second startup, DenovAI.DenovAI will develop an AI-enabled computational biophysics platform that can discover potential antibodies…
Continue Reading
Dr Rocío Acuña Hidalgo, co-founder and CTO at Nostos GenomicsThe sequencing and analysis of human DNA have advanced significantly since the initial draft of a human genome that was published as part of the…
Continue Reading
Mark Diamond, Managing Director and CEO at Antisense Therapeutics Limited joins eHealth Radio and the Health News Channel. Antisense is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet…
Continue Reading
A Chiesi Farmaceutici drug for a rare enzyme deficiency is now approved by the FDA, making it the first U.S. treatment for a disorder that leads to a range of cognitive and muscle problems.
The regulatory decision announced late Thursday covers the treatment of children and adults who have alpha-mannosidosis (AM), a disease caused by a genetic mutation that leads to defective or inactive forms of an enzyme called alpha-D-mannosidase. Chiesi’s drug, velmanase alfa, is an engineered version of that enzyme. The privately held Italian company will market its new FDA-approved drug as Lamzede, the same name for the product in Europe,…
